Project Grant K99AI184587
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant of $379,609.00 to the University of Pittsburgh under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate B cell central tolerance to a model commensal antigen. The project aims to create molecular and cellular tools to study how the immune system establishes homeostasis with commensal microbes, as B cells must balance maintaining a diverse B cell receptor repertoire while...
- This Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to determine how germinal center (GC) responses are controlled in health and how governance loss promotes immune deficiencies and autoimmune diseases. The key objectives are to establish the lineage and functional differences between induced T follicular regulatory (iTFR) and natural TFR (nTFR) cells, and assess...
- This Project Grant award was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855). The $807,799 grant, awarded on July 15, 2025, supports research at the University of Chicago to investigate the role of B cell-dependent regulatory T (BCD Treg) cells in controlling self-reactive B cells and autoantibody production. The project aims to identify BCD Treg cells, define their...
- This Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) provides $115,414 to the Beckman Research Institute of the City of Hope to conduct research aimed at concurrently eradicating pathogenic plasma cells and their precursors in systemic lupus erythematosus (SLE). The award, which runs from September 2024 to August 2026, will support two specific aims: 1) determining the effect of knockdown of the...
- This Project Grant award of $167,915 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to define how B cell receptor binding site (BCRBS) copy number on the plasma membrane is developmentally regulated to optimize antigen recognition and affinity-driven antibody selection. The project aims to utilize a novel BCRBS counter tool to investigate how BCRBS avidity is progressively...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $246,750 to The Trustees of Columbia University in the City of New York to conduct research on the transcriptional and functional identity of human T follicular helper (Tfh) cells across tissue sites. The research aims to systematically analyze Tfh and peripheral helper T (Tph) cells in lymphoid and mucosal tissues, including in early life,...
- This Project Grant award of $441,098 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research by Mayo Clinic to investigate the antagonistic actions of the transcription factors IRF4 and BACH2 in regulating germinal center B cell fates and promoting lymphomagenesis. The research aims to elucidate how the balance between IRF4 and BACH2 controls B cell fate and whether an imbalance...
- This federal Project Grant award of $117,883 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research (CFDA 93.855) program. The grant supports research to investigate how Bruton's Tyrosine Kinase (BTK) uses dimerization to maintain B-cell anergy and prevent autoimmunity. The research aims to 1) determine how BTK dimerization helps it adsorb to plasma membranes, 2) develop a microscopy-based approach to examine how...
- This Project Grant award of $127,273, provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research federal grant program (CFDA 93.846), supports research to investigate the role of the TFEB transcription factor in regulating the metabolic function and autoimmune activity of age-associated B cells (ABCs). The key objectives of this 2-year research project are to: 1) define the metabolic and functional...
- This Project Grant award of $138,126 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research on the role of the transcription factor TCF1 in regulating tissue-resident memory T (TRM) cell formation and maintenance across different tissues. The research aims to address gaps in understanding the mechanisms behind TCF1's regulation of CD8+ T cell fate decisions during acute viral...
ROLE OF THYMIC B CELLS IN IMMUNE TOLERANCE - PROJECT SUMMARY/ABSTRACT GENERATION OF A FUNCTIONAL ADAPTIVE IMMUNE RESPONSE RELIES ON THE COLLABORATION OF THE CELLULAR (T CELL) AND HUMORAL (B CELL) COMPARTMENTS. T FOLLICULAR HELPER (TFH) CELLS PROVIDE ESSENTIAL HELP TO B CELLS TO UNDERGO ISOTYPE CLASS-SWITCH RECOMBINATION AND GENERATE HIGH-AFFINITY ANTIBODY THROUGH SOMATIC HYPERMUTATION. FOLLICULAR REGULATORY T (TFR) CELLS HAVE BEEN IMPLICATED IN CONTROLLING THIS PROCESS AS THEY HAVE BEEN SHOWN TO BE CRITICAL IN REGULATING GERMINAL CENTER B CELL RESPONSES AND PREVENT AUTOANTIBODY FORMATION. HOWEVER, HOW THESE TFR CELLS DEVELOP IS UNKNOWN. B CELLS UNDERGO A UNIQUE TYPE-III INTERFERON DEPENDENT AND ISOTYPE CLASS- SWITCHING PROCESS IN THE THYMUS, THE LOCATION OF T CELL DEVELOPMENT, AND INDUCE CLONAL DELETION AND TREG CELL SELECTION. DEVELOPING TREG CELLS THAT DEPEND ON LICENSED THYMIC B CELL ANTIGENS MAY ALSO INTERACT WITH ACTIVATED B CELLS IN THE PERIPHERY AND TAKE ON A TFR PHENOTYPE. THUS, TREG CELLS SELECTED BY THYMIC B CELLS MAY BECOME TFR CELLS IN THE PERIPHERY AND HELP TO REDUCE THE RISK AUTOANTIBODY GENERATION. THE OBJECTIVE OF THIS WORK IS TO UNDERSTAND WHAT ROLE LICENSED THYMIC B CELLS PLAY IN T CELL TOLERANCE. IN THIS PROPOSAL WE IDENTIFIED T CELL RECEPTORS THAT GENERATE TFR CELLS WHEN EXPRESSED BY DEVELOPING T CELLS, PROPOSE TO STUDY THE REQUIREMENTS OF THESE TCRS FOR SELECTION AS WELL AS EXPLORE FURTHER FUNCTIONAL CONSEQUENCES WHEN THYMIC B CELLS ARE ABSENT. OUR CENTRAL HYPOTHESIS IS THAT TYPE-III INTERFERON DRIVES THYMIC B CELL LICENSING, RESULTING IN THE PRESENTATION OF B CELL ACTIVATION INDUCED SELF-PEPTIDES, THEREBY SUPPORTING THE DEVELOPMENT OF TREG CELLS THAT BECOME TFR CELLS AND REGULATE HUMORAL IMMUNE RESPONSES. THROUGH THIS WORK WE HOPE TO GENERATE A MECHANISTIC UNDERSTANDING OF THE IMPACT OF THYMIC B CELL ACTIVATION ON IMMUNE TOLERANCE. THESE FINDINGS WILL HAVE THE POTENTIAL TO REVEAL NEW PATHWAYS REGULATING ADAPTIVE IMMUNE RESPONSES AND HAVE IMPLICATIONS IN OUR UNDERSTANDING OF AUTOIMMUNE DISEASES LIKE SYSTEMIC LUPUS ERYTHEMATOUS OR RHEUMATOID ARTHRITIS, DISEASES WHERE PATHOGENIC AUTOREACTIVE ANTIBODIES MEDIATE DISEASE. I AM APPLYING FOR THIS K99/R00 AS AN INSTRUCTOR IN LABORATORY MEDICINE AND PATHOLOGY DEPARTMENT WITH SUBSPECIALTY TRAINING IN MOLECULAR PATHOLOGY. MY LONG-TERM CAREER GOALS ARE TO SUPPORT FOR THE CLINICAL DIAGNOSIS OF AUTOIMMUNITY AND INBORN ERRORS OF IMMUNITY AND TO LEAD AN R01 FUNDED RESEARCH PROGRAM THAT INVESTIGATES CENTRAL TOLERANCE AND IMMUNODEFICIENCY.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $138.1k | 7/8/25 | ||
| Not listed | $138.1k | 7/12/24 |